Topic:

Manufacturing

Latest Headlines

Latest Headlines

Sigma-Aldrich purchases Research Organics to expand raw materials portfolio

Sigma-Aldrich has welcomed Research Organics into its growing pharma family, acquiring it for its growing fine chemicals division.

Albany Molecular shutters facility in Hungary, axing 100

Albany Molecular Research has announced plans to close a facility in Budapest, Hungary, axing 100 jobs in the process.

UPDATED: GSK investing in U.K. vaccine manufacturing

GlaxoSmithKline has announced that it intends to invest more than £500 million ($794 million) and create up to 1,000 jobs in vaccine and pharmaceutical manufacturing in the U.K.

GE Healthcare grabs Xcellerex to boost biomanufacturing prowess

GE Healthcare ($GE) is snatching up Xcellerex for an undisclosed price, another step in the company's plans to boost its position in biomanufacturing.

FDA calls on contractors, India to counter Ben Venue drug shortages

A non-FDA approved drug from India and U.S. contract manufacturers will address cancer drug shortages resulting from production and quality problems at Ben Venue Laboratories ' now notorious Ohio...

GSK, bucking industry trend, turns to selective insourcing

GlaxoSmithKline ($GSK) is selectively bringing some manufacturing and other work back under its corporate roof, countering an industry trend that continues to focus on outsourcing vital elements of...

Pew pushes for better FDA oversight of global supply chain

Some consumer advocates are out to make outsourced pharmaceutical manufacturing into a potent political issue in Washington. With the PDUFA reauthorization up for debate, Allan Coukell, director of...

Analysts project red-hot Euro growth for CMO market

One of the big trends in pharma outsourcing in recent years has been a move to contracting out manufacturing services. Frost & Sullivan picked up on that trend in a recent market view, plotting...

Paragon nabs $15M filovirus vax contract from DoD

The U.S. Department of Defense has awarded Paragon Bioservices, a contract manufacturing organization, a $15 million contract to develop a mammalian process to manufacture vaccines for filoviruses,...

Sanofi to relaunch Shan5 in 2013

Sanofi ($SNY) subsidiary Shantha Biotech plans to relaunch the company's pentavalent Shan5 vaccine in 2013. The vaccine was removed from the World Health Organization's prequalification list...